ArticleFrontiers in immunology2023

Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.

Maojin You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.